ASCO 2013 - Poster: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

CHICAGO, IL USA ( - Presented by N.J. Vogelzang,1 S.I. Helle,,2 D.C. Johannessen,3 J.M. O’Sullivan,4 J. Garcia-Vargas,5 C.G. O’Bryan-Tear,6 M. Shan,5 and C. Parker7 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA


asco 2013 vogelzang poster thumb

1Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 2Haukeland University Hospital, Bergen, Norway; 3Ullevål University Hospital, Oslo, Norway; 4Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, Ireland; 5Bayer HealthCare, Montville, NJ, USA; 6Algeta ASA, Oslo, Norway; 7The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK

Click HERE to listen to a podcast by Nicholas Vogelzang, MD, one of the participants in this study.


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage






Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.